Search results for " Survival rate"

showing 10 items of 63 documents

Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer

2019

Research question: Does ovarian stimulation for oocyte vitrification affect disease-free survival and overall survival rates in women with early breast cancer? Design: This cohort study included 259 patients with early breast cancer; 148 patients underwent ovarian stimulation, whereas 111 patients did not. Patients were treated between January 2008 and December 2016. To calculate the disease-free survival time and overall survival rate, the time of definitive surgery was defined as the starting point. The follow-up was conducted up to 5 years. Results: Exposed and non-exposed groups were comparable in tumour, node and metastases classification, Nottingham grade, hormonal receptor status, tu…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentDisease-free survivalStimulationBreast NeoplasmsKaplan-Meier EstimateOverall survival rateGastroenterologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerBreast cancerOvulation InductionInternal medicinemedicineHumansFertility preservationProspective StudiesStage (cooking)Neoplasm MetastasisFertility preservationRetrospective StudiesCryopreservation030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyFertility PreservationHistologymedicine.diseaseVitrificationConfidence intervalSurvival Rate030104 developmental biologyTreatment OutcomeReproductive MedicineOocytesFemaleOvarian stimulationNeoplasm Recurrence LocalbusinessDevelopmental BiologyCohort studyHormoneFollow-Up Studies
researchProduct

Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial …

2021

Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. Materials and methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). Results: Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with …

0301 basic medicineCancer ResearchPrognostic ImpactAnaplastic Lymphoma Kinase/genetics; Child Preschool; Clinical Trials Phase III as Topic; Europe; Female; Follow-Up Studies; Gene Amplification; Humans; Infant; Male; Mutation Rate; N-Myc Proto-Oncogene Protein/genetics; Neuroblastoma/genetics; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival RateEuropean Neuroblastoma Study GroupSIOPENRELAPSE03 medical and health sciencesNeuroblastoma0302 clinical medicineText miningNeuroblastomahemic and lymphatic diseasesREVEALSMedicine and Health SciencesKINASEMedicineHigh risk neuroblastomaHETEROGENEITYCRIZOTINIBSEGMENTAL CHROMOSOMAL ALTERATIONSACTIVATING MUTATIONSPEDIATRIC-PATIENTSbusiness.industryALK receptor tyrosine kinasePoint mutationREARRANGEMENTSCHEMOTHERAPYmedicine.diseaseDoenças Genéticas030104 developmental biologyALKOncology030220 oncology & carcinogenesisCancer researchbusiness
researchProduct

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma

2017

Background: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. Since gemcitabine is widely used in the treatment of leiomyosarcoma and angiosarcoma, we investigated the correlation between hENT1 expression and gemcitabine efficacy in these sarcoma subtypes.Methods: We retrospectively identified 71 patients affected by advanced angiosarcoma (26) or leiomyosarcoma (45) treated within five Italian referral centres for sarcoma; among them, 49 patients (15 angiosarcoma, 34 leiomyosarcoma) were treated…

0301 basic medicineOncologyLeiomyosarcomaMalePathologyCancer ResearchGene ExpressionKaplan-Meier EstimateEquilibrative nucleoside transporter 1Deoxycytidine0302 clinical medicineRetrospective StudieMedicineAngiosarcomaAged 80 and overPredictive markerbiologygemcitabineMiddle AgedSurvival RateOncology030220 oncology & carcinogenesishuman equilibrative nucleoside transporter 1; gemcitabine; leiomyosarcoma; angiosarcomaFemaleSarcomamedicine.drugHumanLeiomyosarcomaAdultmedicine.medical_specialtyAntimetabolites AntineoplasticHemangiosarcomahuman equilibrative nucleoside transporter 1; gemcitabine; leiomyosarcoma; angiosarcoma; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Oncology; Cancer ResearchDisease-Free Survivalhuman equilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 103 medical and health sciencesInternal medicinePancreatic cancerHumansSurvival rateRetrospective StudiesAgedangiosarcomabusiness.industrymedicine.diseaseGemcitabine030104 developmental biologybiology.proteinTranslational Therapeuticsbusiness
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18…

2018

Eser, Sultan (Balikesir Author)

0301 basic medicineUniversal Health Coveragepopulation-based registriesRelative SurvivalSettore MED/42 - Igiene Generale E ApplicataCancer -- TreatmentHumans; Neoplasms; Population Surveillance; Registries; Survival Rate; Medicine (all)0302 clinical medicineNeoplasmsRegistriescancer survivaleducation.field_of_studyRelative survivalMedicine (all)EPICENEGeneral Medicine3. Good healthSurvival Ratetrend030220 oncology & carcinogenesisPopulation SurveillancePublic-Healthcancer surveillanceLiver cancersurvival ; cancer registry ; CONCORD-3CureChildhood-Cancermedicine.medical_specialtypopulation-based cancer registriesWomens CancersPopulationMedicine (all)cancer survival population-based cancer registriesSocio-culturaleUnited-StatessurvivalArticle03 medical and health sciencesBreast cancerCancer epidemiologymedicineHumansNordic-CountriesCancer -- MortalityeducationSurvival rateCancer preventionAlternative Approachbusiness.industryPublic healthCancerCancer -- Patients -- Long-term caremedicine.disease030104 developmental biologyHigh-Income Countries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessDemography
researchProduct

Can We Define the Risk of Lymph Node Metastasis in Early-Stage Cervical Cancer Patients? A Large-Scale, Retrospective Study

2017

BACKGROUND: Sentinel lymph node (SLN) biopsy has emerged as one of the most appreciated techniques for reducing the rate of complete lymph node dissection (LND) performed in patients with early-stage cervical cancer (ECC). However, its performances are still a matter of debate and, to improve them, international guidelines recommend performing at least unilateral LND in case of SLN mapping. In a prior study, we identified a group of patients without evidence of lymph node metastasis (LNM). Our objective is to define a precise risk of LNM for each ECC patient in order to significantly tailor surgery for ECC. METHODS: Clinical and pathological data of ECC patients were retrospectively collect…

AdultAdenocarcinoma; Adult; Aged; Aged 80 and over; Carcinoma Squamous Cell; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Uterine Cervical Neoplasms; Young Adult; Lymph Node Excision; Sentinel Lymph Node Biopsy0301 basic medicinemedicine.medical_specialtySentinel lymph nodeUterine Cervical NeoplasmsAdenocarcinomaLogistic regressionYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansStage (cooking)Large-Scale Retrospective Study Sentinel lymph node (SLN) biopsy Lymphadenectomy (LND) early-stage cervical cancer (ECC)Lymph nodeAgedRetrospective StudiesAged 80 and overCervical cancerSentinel Lymph Node Biopsybusiness.industryRetrospective cohort studyMiddle AgedPrognosismedicine.diseaseSurgerySurvival Ratecervical cancer lymph nodes metastasesDissectionExact testSettore MED/40 - GINECOLOGIA E OSTETRICIA030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisSurgery; OncologyCarcinoma Squamous CellLymph Node ExcisionFemaleSurgeryRadiologybusinessFollow-Up StudiesAnnals of Surgical Oncology
researchProduct

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

2016

Objective The biological heterogeneity of hepatocellular carcinoma (HCC) makes prognosis difficult. We translate the results of a genome-wide high-throughput analysis into a tool that accurately predicts at presentation tumour growth and survival of patients with HCC.Design Ultrasound surveillance identified HCC in 78 (training set) and 54 (validation set) consecutive patients with cirrhosis. Patients underwent two CT scans 6 weeks apart (no treatment in-between) to determine tumour volumes (V-0 and V-1) and calculate HCC doubling time. Baseline-paired HCC and surrounding tissue biopsies for microarray study (Agilent Whole Human Genome Oligo Microarrays) were also obtained. Predictors of su…

AdultMale0301 basic medicinemedicine.medical_specialtyTime FactorsCarcinoma HepatocellularTime FactorMicroarrayHepatocellular carcinomamolecular carcinogenesisGastroenterologyliver imagingHEPATOCELLULAR CARCINOMA; LIVER IMAGING; MOLECULAR CARCINOGENESIS; MOLECULAR ONCOLOGY; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization Pathologic; Prospective Studies; Survival Rate; Time Factors; Tumor Burden; Medicine (all); Gastroenterology03 medical and health sciencesmolecular oncology0302 clinical medicineHepatocellular carcinoma liver imaging molecular carcinogenesis molecular oncologyInternal medicinemedicineCarcinomaHumansDoubling timeProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overNeovascularization Pathologicbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseTumor BurdenSurvival RateProspective Studie030104 developmental biologyQuartileLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionFemalebusinessHumanGut
researchProduct

Use of Hepatitis C-Positive Deceased Liver Donors in Response to the Organ Shortage in an Endemic Area

2017

The region of Sicily, Italy, is witnessing a chronic organ shortage. Thus, to face this critical issue, the use of marginal donors has increased over time. An example of marginal donor expansion is the use of liver donors who are positive for the hepatitis C antibody (HCV+) for HCV+ patients requiring liver transplantation (LT). In view of new advances in HCV therapy, including direct-acting agents (DAAs) to treat HCV in the post-transplant setting, our study focused on a monocentric experience in a series of consecutive LTs performed in adult patients receiving HCV+ liver donor allografts. From 2003 to 2016 at our institute we performed 10 LT using HCV+ deceased donors. In particular, the …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepacivirusHepacivirusLiver transplantationAntiviral AgentsGastroenterologyDonor SelectionFibrosisInternal medicinemedicineHumansAntiviral Agents; Donor Selection; Hepacivirus; Liver TransplantationSurvival rateAgedRetrospective StudiesTransplantationbiologybusiness.industryDonor selectionGraft SurvivalGeneral MedicineHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CTissue DonorsIshak ScoreLiver TransplantationSurvival RateItalyLiverFemaleSteatosisbusinessAntiviral agents Donor selection Hepacivirus Liver transplantation Adult Graft Survival Hepatitis C Liver Liver Transplantation Middle Aged Retrospective Studies Survival Rate Tissue DonorsAnnals of Transplantation
researchProduct

Peri-Tumoral Inflammatory Cell Infiltration in OSCC: A Reliable Marker of Local Recurrence and Prognosis? An Investigation Using Artificial Neural Ne…

2011

The presence of inflammatory reaction in peri-tumoural connective tissue is generally considered as a defense mechanism against cancer, but inflammation tissue in malignant transformation and early steps of oncogenesis has been recently proven to play a supporting and aggravating role in some carcinomas. Aims of this retrospective study were to evaluate in OSCCs the independent association of peri-tumoral inflammatory infiltrate (PTI) with local recurrence (LR) or survival outcome, and to verify whether PTI can be considered a marker of prognosis. Data from 211 cases of OSCC, only surgically treated between 1990 and 2000, were collected and retrospectively analyzed for PTI and the event LR…

AdultMalesurvival ratemedicine.medical_specialtyPathologyoral carcinoma recurrence survival rate markerrecurrenceImmunologyKaplan-Meier EstimateLogistic regressionLower riskGastroenterologyoral carcinomaMalignant transformationSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineCarcinomaHumansImmunology and AllergyStage (cooking)Survival rateAgedNeoplasm StagingAged 80 and overInflammationmarkerPharmacologyUnivariate analysisbusiness.industrymarker; oral carcinoma; recurrence; survival rate;CancerMiddle AgedPrognosismedicine.diseaseTumor BurdenCarcinoma Squamous CellFemaleMouth NeoplasmsNeural Networks ComputerNeoplasm GradingbusinessInternational Journal of Immunopathology and Pharmacology
researchProduct

Influence of Intraperitoneal Dissemination Assessed by Laparoscopy on Prognosis of Advanced Ovarian Cancer: An Exploratory Analysis of a Single-Insti…

2014

Purpose: The aim of this study was to investigate whether preoperative laparoscopic evaluation of the dissemination of disease may have an independent impact on survival in advanced epithelial ovarian cancer (AEOC).Methods: All AEOC women were submitted to staging laparoscopy before receiving primary debulking surgery (PDS) or neoadjuvant chemotherapy (NACT). All study women received a laparoscopic score (predictive index value [PIV]) and were stratified into three groups based on volume of disease: high tumor load (HTL) for PIV ≥8, intermediate tumor load (ITL) for PIV equal to 6 and 4, and low tumor load (LTL) for PIV 1 cm in 15 cases (9.1 %). When stratifying the whole population accordi…

AdultOncologymedicine.medical_specialtyNeoplasm ResidualAdult; Aged; Aged; 80 and over; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Laparoscopy; Middle Aged; Neoplasm Staging; Neoplasm; Residual; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor BurdenPopulationlaparoscopySurgical oncologyInternal medicineHumansMedicineeducationLaparoscopySurvival ratePeritoneal NeoplasmsAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian Neoplasmseducation.field_of_studymedicine.diagnostic_testPerformance statusbusiness.industryMedicine (all)Retrospective cohort studyMiddle AgedPrognosismedicine.diseaseDebulkingCombined Modality TherapyTumor BurdenSurvival Rateovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyFemaleSurgerybusinessOvarian cancerFollow-Up StudiesAnnals of Surgical Oncology
researchProduct